Estrogens and bone disease in chronic kidney disease: Role of FGF23

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 4, 2010, Pages 354-358

  Cannata Andía, Jorge B ^a   Carrillo López, Natalia ^a   Naves Díaz, Manuel ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

chronic kidney disease; estrogens; FGF23; parathyroid hormone

Indexed keywords

CALCITRIOL; CALCIUM; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FIBROBLAST GROWTH FACTOR 23; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; PARATHYROID HORMONE; PHOSPHORUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; FIBROBLAST GROWTH FACTOR;

BONE METABOLISM; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; ESTROGEN RESPONSIVE ELEMENT; FRACTURE; METABOLIC BONE DISEASE; NONHUMAN; OSSIFICATION; OSTEOCLAST ACTIVITY; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; ANIMAL; BONE; BONE DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG EFFECTS; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; BONE DISEASES; ESTROGENS; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; SIGNAL TRANSDUCTION; VITAMIN D;

EID: 77954080241     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328338f508     Document Type: Review

References (52)

1. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115:3318-3325.
2. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21:115-137.
3. Kousteni S, Chen JR, Bellido T, et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002; 298:843-846.
4. Zallone A. Direct and indirect estrogen actions on osteoblasts and osteo-clasts. Ann N Y Acad Sci 2006; 1068:173-179.
5. Krum SA, Miranda-Carboni GA, Hauschka PV, et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008; 27:535-545.
6. Liel Y, Shany S, Smirnoff P, Schwartz B. Estrogen increases 1,25-dihydrox-yvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology 1999; 140:280-285.
7. Ten Bolscher M, Netelenbos JC, Barto R, et al. Estrogen regulation of intestinal calcium absorption in the intact and ovariectomized adult rat. J Bone Miner Res 1999; 14:1197-1202.
8. Irnaten M, Blanchard-Gutton N, Praetorius J, Harvey BJ. Rapid effects of 17beta-estradiol on TRPV5 epithelial Ca2+ channels in rat renal cells. Steroids 2009; 74:642-649.
9. Faroqui S, Levi M, Soleimani M, Amlal H. Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia. Kidney Int 2008; 73:1141-1150.
10. Pinkerton JV, Dalkin AC. Combination therapy for treatment of osteoporosis: a review. Am J Obstet Gynecol 2007; 197:559-565.
11. Stock JL, Coderre JA, Mallette LE. Effects of a short course of estrogen on mineral metabolism in postmenopausal women. J Clin Endocrinol Metab 1985; 61:595-600.
12. Naveh-Many T, Almogi G, Livni N, Silver J. Estrogen receptors and biologic response in rat parathyroid tissue and C cells. J Clin Invest 1992; 90:2434-2438.
13. Carrillo-Lopez N, Roman-Garcia P, Rodriguez-Rebollar A, et al. Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol 2009; 20:2009-2017.
14. Holley JL, Schmidt RJ. Hormone replacement therapy in postmenopausal women with end-stage renal disease: a review of the issues. Semin Dial 2001; 14:146-149.
15. Weisinger JR. Role of hormone replacement in the management of osteoporosis in haemodialysed women: perspectives for the future. Nephrol Dial Transplant 2000; 15 (Suppl 5):36-37.
16. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006; 116:1186-1194.
17. Rodriguez-Rodriguez A, Naves M, Rodriguez-Rebollar A, et al. Hormonal replacement therapy in an animal model with chronic renal failure and ovariectomy: biochemical and densitometric study. Kidney Int 2003; 63 (Suppl 85):57-61.
18. Naves-Diaz M, Rodriguez-Rodriguez A, Fernandez-Martin JL, et al. Effects of estradiol, calcitriol and both treatments combined on bone histomorphometry in rats with chronic kidney disease and ovariectomy. Bone 2007; 41:614-619.
19. Seeman E, Crans GG, Diez-Perez A, et al. Antivertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 2006; 17:313-316.
20. Naves-Diaz M, Carrillo-Lopez N, Rodriguez-Rodriguez A, et al. Differential effects of 17p-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency. Menopause (in press).
21. Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007; 130:811-823.
22. Lerner UH. Bone remodeling in postmenopausal osteoporosis. J Dent Res 2006; 85:584-595.
23. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 2000; 24:145-155.
24. Dahlman-Wright K, Cavailles V, Fuqua SA, et al. International union of pharmacology. LXIV: Estrogen receptors. Pharmacol Rev 2006; 58:773-781.
25. Venken K, Callewaert F, Boonen S, Vanderschueren D. Sex hormones, their receptors and bone health. Osteoporos Int 2008; 19:1517-1525.
26. McKane WR, Khosla S, Burritt MF, et al. Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postme-nopause: a clinical research center study. J Clin Endocrinol Metab 1995; 80:3458-3464.
27. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002; 9:601-610.
28. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 2005; 5:343-357.
29. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev 2001; 81:1535-1565.
30. Hall JM, Couse JF, Korach KS.The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001; 276:36869-36872.
31. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001; 29:2905-2919.
32. Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000; 74:311-317.
33. Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001; 62:231-252.
34. Safe S, Kim K. Nonclassical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 2008; 41:263-275.
35. Weigel NL, Zhang Y. Ligand-independent activation of steroid hormone receptors. J Mol Med 1998; 76:469-479.
36. Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genom 2006; 7:497-508.
37. Malyala A, Kelly MJ, Ronnekleiv OK. Estrogen modulation of hypothalamic neurons: activation of multiple signaling pathways and gene expression changes. Steroids 2005; 70:397-406.
38. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000; 407:538-541.
39. Klinge CM, Blankenship KA, Risinger KE, et al. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem 2005; 280:7460-7468.
40. Incerpi S, D'Arezzo S, Marino M, et al. Short-term activation by low 17beta-estradiol concentrations of the Na+/H+ exchanger in rat aortic smooth muscle cells: physiopathological implications. Endocrinology 2003; 144:4315-4324.
41. Kousteni S, Han L, Chen JR, et al. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 2003; 111:1651-1664.
42. Michael H, Harkonen PL, Vaananen HK, Hentunen TA. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 2005; 20:2224-2232.
43. Khosla S, Atkinson EJ, Melton LJ 3rd, Riggs BL. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. J Clin Endocrinol Metab 1997; 82:1522-1527.
44. Zhang Y, Lai WP, Wu CF, et al. Ovariectomy worsens secondary hyperparathyroidism in mature rats during low-Cadiet. Am J Physiol 2007; 292:E723-E731.
45. Colin EM, Van Den Bemd GJ, Van Aken M, et al. Evidence for involvement of 17beta-estradiol in intestinal calcium absorption independent of 1,25-dihydroxyvitamin D3 level in the Rat. J Bone Miner Res 1999; 14:57-64.
46. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98:6500-6505.
47. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007; 293:F1577-F1583.
48. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117:4003-4008.
49. Hughes DE, Dai A, Tiffee JC, et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996; 2:1132-1136.
50. Chow J, Tobias JH, Colston KW, Chambers TJ. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J Clin Invest 1992; 89:74-78.
51. Qu Q, Perala-Heape M, Kapanen A, et al. Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone 1998; 22:201-209.
52. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584-592.